Hemtex’s rights issues oversubscribed

Report this content

Calculation of the outcome of the rights issue implemented by Hemtex AB (publ)(“Hemtex”) shows that the issue was oversubscribed, which means that the guarantee commitment that had been entered into need not be utilized. As a result of the rights issue, Hemtex will receive approximately SEK 164 million before issue expenses.

Of the rights issue, 99.3 percent, corresponding to 11,658,080 shares, was subscribed for on the basis of subscription rights. Applications to subscribe for shares without the support of subscription rights were made for approximately 258.3 percent of the total issue, corresponding to 30,305,589 shares. New shares subscribed for without the support of subscription rights were allotted to the shareholders who had subscribed for shares on the basis of subscription rights, in accordance with the principles stated in the prospectus published on April 27, 2009. A statement will be issued on or around May 20, 2009 confirming allotment of new shares to those subscribers who subscribed for new shares without the support of subscription rights. “It is extremely encouraging knowing that Hemtex shareholders have given 100% support to the rights issue. Accordingly, the foundation for the efforts to forcefully enhance Hemtex’s profitability has now been laid,” says Mats Olsson, Chairman of the Hemtex Board. As a result of the rights issue, the number of Hemtex shares will increase by 11,734,960 to 41,072,360. The share capital will increase by SEK 29,337,400 to SEK 102,680,900. Paid subscribed shares (BTAs) will be traded on NASDAQ OMX Stockholm until partial registration of the new shares with the Swedish Companies Registration Office has been effected. In the event that several classes of BTAs are issued, only the first class will be traded on NASDAQ OMX Stockholm. The re-registration of the BTAs as new shares will occur on or around May 28, 2009, whereby the new shares will become subject to trading on NASDAQ OMX Stockholm.

Tags:

Documents & Links